N.A. Beelen
Recente publicaties
-
Poissonnier, A., Rugo, H. S., Horton, W., Kim, T., DeLuca, A., Egeland, E. V., Cotechini, T., Sivagnanam, S., Mori, M., Yu, Y., Park, B., Beelen, N., Murugan, D., Kirchberger, N., Kummar, S., Mayer, I. A., Blackwell, K., Hwang, E. S., & Coussens, L. M. (2026). CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors. Clinical Cancer Research, 32(14), 2832-2849. https://doi.org/10.1158/1078-0432.CCR-25-4236Meer informatie over deze publicatie
-
Barbeau, L. M. O., Beelen, N. A., Savelkouls, K. G., Keulers, T. G. H., Wieten, L., & Rouschop, K. M. A. (2025). MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer. PLOS ONE, 20(2), Article e0316716. https://doi.org/10.1371/journal.pone.0316716Meer informatie over deze publicatie
-
Beelen, N. A., Valckx, V. T. C., Bos, G. M. J., & Wieten, L. (2024). Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy. Best Practice & Research Clinical Haematology, 37(3), Article 101568. https://doi.org/10.1016/j.beha.2024.101568Meer informatie over deze publicatie
-
Beelen, N. A., Molenbroeck, S. J. J., Groeneveld, L., Voorter, C. E., Bos, G. M. J., & Wieten, L. (2024). HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma. Immunogenetics, 76(3), 155-164. https://doi.org/10.1007/s00251-024-01336-wMeer informatie over deze publicatie
-
Beelen, N. A. (2024). Natural killer cells in the tumor microenvironment: Enhancing immunotherapy by exploring the communication between NK cells and tumor cells. [Doctoral Thesis, Maastricht University]. Maastricht University. https://doi.org/10.26481/dis.20240426nbMeer informatie over deze publicatie
-
Beelen, N. A., Aberle, M. R., Bruno, V., Olde Damink, S. W. M., Bos, G. M. J., Rensen, S. S., & Wieten, L. (2023). Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Frontiers in Immunology, 14(1), Article 1133796. https://doi.org/10.3389/fimmu.2023.1133796Meer informatie over deze publicatie
-
Beelen, N. A., Ehlers, F. A. I., Bos, G. M. J., & Wieten, L. (2023). Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunology Immunotherapy, 72(4), 797-804. https://doi.org/10.1007/s00262-022-03299-xMeer informatie over deze publicatie
-
Beelen, N. A., Ehlers, F. A. I., Kooreman, L. F. S., Bos, G. M. J., & Wieten, L. (2023). An in vitro model to monitor natural killer cell effector functions against breast cancer cells derived from human tumor tissue. In C. Thomas, & L. Galluzzi (Eds.), The Immunological Synapse Part A (1 ed., Vol. 173, pp. 133-153). Academic Press. https://doi.org/10.1016/bs.mcb.2022.05.001Meer informatie over deze publicatie
-
Beaumont, J. E. J., Beelen, N. A., Wieten, L., & Rouschop, K. M. A. (2022). The Immunomodulatory Role of Hypoxic Tumor-Derived Extracellular Vesicles. Cancers, 14(16), Article 4001. https://doi.org/10.3390/cancers14164001Meer informatie over deze publicatie
-
Sheffer, M., Lowry, E., Beelen, N., Borah, M., Naffar-Abu Amara, S., Mader, C. C., Roth, J. A., Tsherniak, A., Freeman, S. S., Dashevsky, O., Gandolfi, S., Bender, S., Bryan, J. G., Zhu, C., Wang, L., Tariq, I., Kamath, G. M., Simoes, R. D., Dhimolea, E., ... Mitsiades, C. S. (2021). Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nature Genetics, 53(8), 1196-1206. https://doi.org/10.1038/s41588-021-00889-wMeer informatie over deze publicatie